Ever Supreme Bio Technology Geçmiş Kazanç Performansı
Hala bu şirketin son kazanç raporunu inceliyoruz
Geçmiş kriter kontrolleri 4/6
Ever Supreme Bio Technology has been growing earnings at an average annual rate of 58.6%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 51.5% per year. Ever Supreme Bio Technology's return on equity is 33.1%, and it has net margins of 62%.
Anahtar bilgiler
58.6%
Kazanç büyüme oranı
58.7%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 12.2% |
Gelir büyüme oranı | 51.5% |
Özkaynak getirisi | 33.1% |
Net Marj | 62.0% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Ever Supreme Bio Technology nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 824 | 511 | 49 | 103 |
31 Mar 24 | 805 | 446 | 49 | 101 |
31 Dec 23 | 758 | 539 | 48 | 99 |
30 Sep 23 | 683 | 571 | 45 | 95 |
30 Jun 23 | 628 | 335 | 41 | 95 |
31 Mar 23 | 621 | 326 | 40 | 90 |
31 Dec 22 | 628 | 201 | 40 | 91 |
30 Sep 22 | 603 | 153 | 45 | 97 |
30 Jun 22 | 575 | 348 | 45 | 85 |
31 Mar 22 | 513 | 374 | 43 | 87 |
31 Dec 21 | 439 | 370 | 45 | 84 |
30 Sep 21 | 310 | 261 | 39 | 79 |
30 Jun 21 | 193 | 15 | 36 | 90 |
31 Mar 21 | 112 | -94 | 35 | 100 |
31 Dec 20 | 71 | -107 | 30 | 109 |
30 Sep 20 | 53 | -118 | 42 | 119 |
30 Jun 20 | 28 | -124 | 43 | 110 |
31 Mar 20 | 19 | -102 | 43 | 100 |
31 Dec 19 | 11 | -94 | 43 | 95 |
30 Sep 19 | 2 | -80 | 30 | 89 |
30 Jun 19 | 0 | -85 | 29 | 92 |
31 Mar 19 | 0 | -77 | 25 | 83 |
31 Dec 18 | 0 | -69 | 21 | 73 |
30 Sep 18 | 0 | -56 | 17 | 60 |
30 Jun 18 | 0 | -43 | 13 | 46 |
31 Mar 18 | 0 | -37 | 12 | 38 |
31 Dec 17 | 0 | -31 | 11 | 29 |
Kaliteli Kazançlar: 6712 has a large one-off gain of NT$170.3M impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: 6712's current net profit margins (62%) are higher than last year (53.3%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 6712 has become profitable over the past 5 years, growing earnings by 58.6% per year.
Büyüme Hızlandırma: 6712's earnings growth over the past year (52.5%) is below its 5-year average (58.6% per year).
Kazançlar vs. Sektör: 6712 earnings growth over the past year (52.5%) exceeded the Biotechs industry 33.2%.
Özkaynak Getirisi
Yüksek ROE: 6712's Return on Equity (33.1%) is considered high.